tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Vertex Pharmaceuticals Inc

VRTX
Add to Watchlist
546.120USD
-11.840-2.12%
Close 09-04 16:00（ET）
138.38BMarket Cap
32.12P/E TTM

Vertex Pharmaceuticals Inc

546.120
-11.840-2.12%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

VRTX Financials

See Vertex Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Vertex Pharmaceuticals Inc Earnings Date

Latest Release
Aug 3, 2026
EPS / Forecast
4.34/4.73
Revenue / Forecast
3.33B/3.23B
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
12.00B
8.90%
EPS(YoY)
15.46
844.44%
Analyst Rating
BUY
2026/09/06
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
7.74%4.34
61.34%4.06
32.36%4.70
4.56%4.24
128.90%4.02
-40.93%2.52
-5.61%3.55
0.98%4.05
-491.83%-13.92
56.64%4.26
17.98%3.76
--4.01
--3.55
--2.72
--3.19
--9.79
----
----
----
----
Revenue
12.45%3.33B
7.82%2.99B
9.55%3.19B
10.99%3.08B
12.06%2.96B
2.96%2.77B
15.66%2.91B
11.61%2.77B
6.11%2.65B
13.30%2.69B
9.34%2.52B
6.39%2.48B
13.52%2.49B
13.22%2.37B
11.10%2.30B
17.65%2.33B
22.46%2.20B
21.64%2.10B
27.32%2.07B
28.99%1.98B
Net Profit
6.48%1.10B
59.59%1.03B
30.46%1.19B
3.59%1.08B
128.74%1.03B
-41.22%646.30M
-5.76%913.00M
0.98%1.05B
-492.44%-3.59B
57.13%1.10B
18.31%968.80M
11.26%1.04B
12.98%915.70M
-8.17%699.80M
6.34%818.90M
9.22%930.50M
1111.08%810.50M
16.68%762.10M
27.46%770.11M
27.64%851.93M
Net Margin
-5.31%32.99%
48.01%34.53%
19.09%37.34%
-6.67%35.20%
125.65%34.84%
-42.91%23.33%
-18.52%31.35%
-9.53%37.71%
-469.84%-135.83%
38.69%40.87%
8.20%38.48%
--41.69%
--36.73%
--29.47%
--35.56%
--37.77%
----
----
----
----
Gross Margin
-1.08%85.33%
-0.05%86.85%
-0.08%85.39%
0.79%86.52%
0.36%86.25%
-0.42%86.90%
0.09%85.46%
-1.53%85.84%
-1.92%85.94%
-1.68%87.27%
-2.64%85.38%
--87.17%
--87.62%
--88.76%
--87.70%
--87.98%
----
----
----
----
Debt to assets ratio
----
----
-16.88%0.42%
----
----
-67.79%0.49%
-69.75%0.50%
-71.47%0.51%
-13.30%1.72%
-31.33%1.51%
-30.29%1.65%
--1.80%
--1.99%
--2.20%
--2.37%
--2.65%
----
----
----
----
Income Statement
Revenue
12.45%3.33B
7.82%2.99B
9.55%3.19B
10.99%3.08B
12.06%2.96B
2.96%2.77B
15.66%2.91B
11.61%2.77B
6.11%2.65B
13.30%2.69B
9.34%2.52B
6.39%2.48B
13.52%2.49B
13.22%2.37B
11.10%2.30B
17.65%2.33B
22.46%2.20B
21.64%2.10B
27.32%2.07B
28.99%1.98B
Operating profit
9.92%1.27B
10.45%1.14B
13.58%1.26B
9.47%1.24B
23.46%1.15B
-15.22%1.03B
16.35%1.11B
3.72%1.13B
-17.72%934.90M
8.18%1.22B
-9.63%956.00M
-5.39%1.09B
0.38%1.14B
8.79%1.12B
20.80%1.06B
9.22%1.15B
3213.23%1.13B
16.91%1.03B
17.34%875.72M
56.62%1.06B
Net Profit
6.48%1.10B
59.59%1.03B
30.46%1.19B
3.59%1.08B
128.74%1.03B
-41.22%646.30M
-5.76%913.00M
0.98%1.05B
-492.44%-3.59B
57.13%1.10B
18.31%968.80M
11.26%1.04B
12.98%915.70M
-8.17%699.80M
6.34%818.90M
9.22%930.50M
1111.08%810.50M
16.68%762.10M
27.46%770.11M
27.64%851.93M
Balance Sheet
Current assets
20.29%12.54B
17.20%11.73B
16.72%11.20B
7.81%10.57B
16.62%10.43B
-24.68%10.01B
-32.15%9.60B
-33.29%9.80B
-35.55%8.94B
2.49%13.29B
6.87%14.14B
19.76%14.70B
20.60%13.87B
25.14%12.97B
38.43%13.23B
38.62%12.27B
36.02%11.50B
21.34%10.36B
17.55%9.56B
18.69%8.85B
Total current liabilities
-4.84%3.94B
2.57%3.88B
8.32%3.86B
12.64%4.48B
16.67%4.14B
-0.33%3.78B
0.48%3.56B
10.38%3.97B
5.82%3.55B
25.43%3.80B
29.37%3.55B
37.95%3.60B
31.14%3.35B
38.80%3.03B
28.02%2.74B
36.31%2.61B
39.19%2.56B
12.15%2.18B
14.09%2.14B
-4.48%1.91B
Total assets
14.09%27.42B
15.75%26.48B
13.80%25.64B
11.79%24.86B
19.39%24.04B
-4.34%22.88B
-0.87%22.53B
2.37%22.24B
-1.07%20.13B
26.05%23.92B
25.23%22.73B
30.05%21.73B
30.59%20.35B
33.10%18.97B
35.13%18.15B
32.39%16.71B
27.50%15.58B
17.67%14.26B
14.30%13.43B
11.65%12.62B
Total liabilities
4.58%7.18B
11.56%7.12B
13.94%6.98B
14.13%7.54B
28.07%6.86B
18.87%6.38B
18.91%6.12B
26.78%6.61B
9.81%5.36B
18.25%5.37B
21.51%5.15B
41.79%5.21B
33.72%4.88B
35.62%4.54B
27.18%4.24B
19.07%3.68B
20.61%3.65B
6.84%3.35B
8.73%3.33B
-2.53%3.09B
Total equity
17.89%20.25B
17.37%19.36B
13.75%18.67B
10.80%17.32B
16.25%17.18B
-11.05%16.50B
-6.66%16.41B
-5.34%15.63B
-4.50%14.77B
28.51%18.55B
26.36%17.58B
26.73%16.51B
29.64%15.47B
32.32%14.43B
37.75%13.91B
36.71%13.03B
29.76%11.93B
21.46%10.91B
16.27%10.10B
17.18%9.53B
Cash Flow Statement
Net operating income
4.87%1.13B
74.39%1.43B
-14.81%498.00M
-9.37%1.24B
128.59%1.07B
-37.33%818.90M
149.19%584.60M
7.99%1.37B
-430.89%-3.75B
45.19%1.31B
-78.25%234.60M
32.75%1.27B
-0.47%1.13B
-5.89%899.90M
8.38%1.08B
3.05%955.50M
670.56%1.14B
3.82%956.20M
102.43%994.99M
2.14%927.22M
Net investment
90.55%-45.80M
-674.01%-431.90M
64.95%-288.10M
66.38%-117.00M
-4.49%-484.50M
97.39%-55.80M
7.29%-821.90M
-195.67%-348.00M
-52.58%-463.70M
-16.51%-2.14B
-604.84%-886.50M
69.36%-117.70M
-394.15%-303.90M
-3495.29%-1.83B
231.05%175.60M
-625.56%-384.20M
22.78%-61.50M
31.37%-51.00M
-154.97%-134.00M
78.64%-52.95M
Net financing
-22.19%-426.70M
20.81%-538.80M
80.27%-77.20M
-197.94%-1.15B
2.62%-349.20M
-90.32%-680.40M
-226.63%-391.30M
-134.85%-387.50M
-2172.83%-358.60M
-21.31%-357.50M
-398.01%-119.80M
-174.09%-165.00M
-63.73%17.30M
-208.91%-294.70M
111.96%40.20M
90.83%-60.20M
42.18%47.70M
81.61%-95.40M
-168.58%-336.24M
-366.76%-656.66M

FAQs

What is the total revenue of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 12.00B, with a year-on-year change of 11.02B.

What are the current assets of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its current assets were 11.20B, with a year-on-year change of 16.72.

What are the total assets of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its total assets of Vertex Pharmaceuticals Inc were 25.64B, with a year-on-year change of 13.80.

What are the total liabilities of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Vertex Pharmaceuticals Inc were 6.98B, with a year-on-year change of 13.94.

What is the total equity of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its total equity of Vertex Pharmaceuticals Inc was 18.67B, with a year-on-year change of 13.75.

What is the net operating income of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Vertex Pharmaceuticals Inc was 4.69B, with a year-on-year change of 6.65.

What is the net investment of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its net investment of Vertex Pharmaceuticals Inc was -945.40M, with a year-on-year change of 74.92.

What is the net financing of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its net financing of Vertex Pharmaceuticals Inc was -2.26B, with a year-on-year change of -51.27.

What is the Earnings Per Share (EPS) of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 15.46, with a year-on-year change of 844.44.

What is the net income of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its net income was 3.95B, with a year-on-year change of 838.09.

What is the net margin of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 32.94, with a year-on-year change of 777.74.

What is the gross margin of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 86.24, with a year-on-year change of 0.15.

What is the debt-to-asset ratio of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 0.44, with a year-on-year change of -16.45.

What is the Return on Equity (ROE) of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was 22.54, with a year-on-year change of 815.25.

What is the Return on Assets (ROA) of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 16.41, with a year-on-year change of 793.46.

What is the operating profit of Vertex Pharmaceuticals Inc?

According to Vertex Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 4.69B, with a year-on-year change of 6.65.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy